In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvanDx's 90-minute Staphylococcus tests cleared by FDA

This article was originally published in Clinica

Executive Summary

The US FDA has granted 510(k) clearance for a 90-minute protocol for AdvanDx's S aureus PNA FISH and S aureus/CNS PNA FISH tests. Both tests use fluorescence in situ hybridisation (FISH), the former to detect Staphylococcus aureus bloodstream infections, and the latter to identify coagulase-negative staphylococci (CNS). True S aureus infections can cause life-threatening problems, while blood culture contamination with CNS can lead to a false diagnosis of staphylococcal infection. These patients then receive unnecessary antibiotic treatment. The original tests took 2.5 hours to produce results – the new versions have reduced peptide nucleic acid (PNA) time from 90 to 30 minutes while maintaining high sensitivity and specificity, the Woburn, Massachusetts firm claims.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT045014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel